OBJECTIVE: The objective of the study was to assess the incidence of, and risk factors for, abnormal anal cytology and anal intraepithelial neoplasia (AIN) 2-3 in human immunodeficiency virus (HIV)-infected women. STUDY DESIGN: This prospective study assessed 100 HIV-infected women with anal and cervical specimens for cytology and high-risk human papillomavirus (HPV) testing over 3 semiannual visits. RESULTS: Thirty-three women were diagnosed with an anal cytologic abnormality at least once. Anal cytology abnormality was associated with current CD4 count less than 200 cells/mm(3), anal HPV infection, and a history of other sexually transmitted infections (STIs). Twelve subjects were diagnosed with AIN2-3: 4 after AIN1 diagnosis and 4 after 1 or more negative anal cytology. AIN2-3 trended toward an association with history of cervical cytologic abnormality and history of STI. CONCLUSION: Repeated annual anal cytology screening for HIV-infected women, particularly for those with increased immunosuppression, anal and/or cervical HPV, a history of other STIs, or abnormal cervical cytology, will increase the likelihood of detecting AIN2-3.
OBJECTIVE: The objective of the study was to assess the incidence of, and risk factors for, abnormal anal cytology and anal intraepithelial neoplasia (AIN) 2-3 in human immunodeficiency virus (HIV)-infectedwomen. STUDY DESIGN: This prospective study assessed 100 HIV-infectedwomen with anal and cervical specimens for cytology and high-risk human papillomavirus (HPV) testing over 3 semiannual visits. RESULTS: Thirty-three women were diagnosed with an anal cytologic abnormality at least once. Anal cytology abnormality was associated with current CD4 count less than 200 cells/mm(3), anal HPV infection, and a history of other sexually transmitted infections (STIs). Twelve subjects were diagnosed with AIN2-3: 4 after AIN1 diagnosis and 4 after 1 or more negative anal cytology. AIN2-3 trended toward an association with history of cervical cytologic abnormality and history of STI. CONCLUSION: Repeated annual anal cytology screening for HIV-infectedwomen, particularly for those with increased immunosuppression, anal and/or cervical HPV, a history of other STIs, or abnormal cervical cytology, will increase the likelihood of detecting AIN2-3.
Authors: Irving E Salit; Alice Lytwyn; Janet Raboud; Marie Sano; Sylvia Chong; Christina Diong; William Chapman; James B Mahony; Jill Tinmouth Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Andrea Gingelmaier; Tobias Weissenbacher; Bernd Kost; Ralph Kaestner; Milena Sovric; Ioannis Mylonas; Klaus Friese; Florian Bergauer Journal: Anticancer Res Date: 2010-05 Impact factor: 2.480
Authors: Mark Bower; Tom Powles; Tom Newsom-Davis; Christina Thirlwell; Justin Stebbing; Sundihya Mandalia; Mark Nelson; Brian Gazzard Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: Amanda J Durante; Ann B Williams; Maria Da Costa; Teresa M Darragh; Kaveh Khoshnood; Joel M Palefsky Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-07 Impact factor: 4.254
Authors: Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky Journal: J Low Genit Tract Dis Date: 2015-07 Impact factor: 1.925
Authors: Elizabeth A Stier; Meagan C Sebring; Audrey E Mendez; Fatimata S Ba; Debra D Trimble; Elizabeth Y Chiao Journal: Am J Obstet Gynecol Date: 2015-03-19 Impact factor: 8.661
Authors: Tracy A Battaglia; Christine M Gunn; Molly E McCoy; Helen H Mu; Amy S Baranoski; Elizabeth Y Chiao; Lisa A Kachnic; Elizabeth A Stier Journal: Womens Health Issues Date: 2015-08-04
Authors: Lois J Conley; Timothy J Bush; Teresa M Darragh; Joel M Palefsky; Elizabeth R Unger; Pragna Patel; Martin Steinau; E Milu Kojic; Harold Martin; E Turner Overton; Susan Cu-Uvin; John Hammer; Keith Henry; Kathleen Wood; John T Brooks Journal: J Infect Dis Date: 2015-08-12 Impact factor: 5.226